Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 429Breast Neoplasms 300Neoplasms 297Colorectal Neoplasms 242Neoplasm Metastasis 197Ovarian Neoplasms 171Lung Neoplasms 150Prostatic Neoplasms 149Recurrence 147Pancreatic Neoplasms 142Multiple Myeloma 136Stomach Neoplasms 130Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 115Advanced Solid Tumors 114Advanced Solid Tumor 109Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Safety Issues × Clear all
NCT05142592 2025-09-24

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Nanjing Immunophage Biotech Co., Ltd

Phase 1/2 Recruiting
196 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡